Physician

Mohammad Ali Syed Jafri, M.D.

According to 2025 Medicare claims, Mohammad Jafri, M.D. (NPI: 1629311774) practices hematology/oncology in the Victoria, TX market, with the plurality of this provider's patient population coming from Victoria, TX. This provider's primary affiliated billing organization is REGIONAL EMPLOYEE ASSISTANCE PROGRAM INC (NPI: 1215999511; TIN: 621762428) and primary practice location at 77901-6004. Jafri is affiliated with the CHSPSC ACO 14, LLC (ACO ID: A3724), The Rural Advantage LLC (ACO ID: A5257), Main Street Rural Health Hickory ACO LLC (ACO ID: A5334), Main Street Rural Health Magnolia ACO LLC (ACO ID: A5400), Main Street Rural Health Cottonwood ACO LLC (ACO ID: A5439), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Jafri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 584 traditional Medicare patients, billed 2,867 HCPCS/CPT codes, and received $250,226 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,559 prescription claims across 247 beneficiaries totaling $3,832,674 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 105 claims. Open Payments data shows 108 records totaling $22,360. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,189 to $250,226. Similarly, Part D prescription costs have risen steadily, from $24,220 to $3,832,674. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	15	20	$2,189
2017	244	400	$37,476
2018	448	908	$80,655
2019	107	287	$30,007
2020	263	807	$48,737
2021	180	1,247	$61,072
2022	45	2,780	$69,685
2023	345	1,515	$138,575
2024	584	2,867	$250,226

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	44	170	$24,220
2016	45	175	$120,342
2017	75	242	$279,535
2018	70	206	$183,909
2019	16	39	$1,677
2020	82	304	$333,471
2021	163	569	$443,834
2022	179	892	$818,863
2023	124	610	$552,558
2024	247	1,559	$3,832,674

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	105	$4,551
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	133	169	$131
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	108	108	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	404	1,286	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	193	307	$67
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	132	612	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	54	1,358	$882,070
Jakafi	Ruxolitinib Phosphate	23	690	$392,441
Ojjaara	Momelotinib Dihydrochloride	11	330	$312,271
Kisqali	Ribociclib Succinate	18	483	$297,560
Lenvima	Lenvatinib Mesylate	11	330	$263,737

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	108	$22,360	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad Ali Syed Jafri, M.D.?

Tedicare shows public-source Medicare data for Mohammad Ali Syed Jafri, M.D. (NPI 1629311774), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad Ali Syed Jafri, M.D. have ACO affiliation data?

Mohammad Ali Syed Jafri, M.D. is shown with ACO affiliation data for CHSPSC ACO 14, LLC (MSSP, ACO ID A3724), The Rural Advantage LLC (MSSP, ACO ID A5257), Main Street Rural Health Hickory ACO LLC (MSSP, ACO ID A5334), Main Street Rural Health Magnolia ACO LLC (MSSP, ACO ID A5400), Main Street Rural Health Cottonwood ACO LLC (MSSP, ACO ID A5439), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mohammad Ali Syed Jafri, M.D.?

Mohammad Ali Syed Jafri, M.D. is linked to REGIONAL EMPLOYEE ASSISTANCE PROGRAM INC (billing NPI 1215999511) in the available physician profile data.

Does Mohammad Ali Syed Jafri, M.D. have Open Payments data?

Mohammad Ali Syed Jafri, M.D. has 108 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.